Based on Phase 2 and early Phase 3 data, retatrutide has a safety profile similar to other GLP-1 medications. Most side effects are mild to moderate and decrease over time. However, retatrutide is still investigational and has not yet received FDA approval, so long-term safety data is limited.

What makes retatrutide side effects different from other GLP-1 drugs?

Retatrutide is a triple agonist (GIP + GLP-1 + glucagon), unlike semaglutide (GLP-1 only) or tirzepatide (GIP + GLP-1). The additional glucagon receptor activity may cause slightly different metabolic effects, but the main side effects remain gastrointestinal and are similar across all three drug classes.

Retatrutide Side Effects: What Clinical Trials Show So Far

Q: What are the most common retatrutide side effects?

The most common retatrutide side effects are gastrointestinal: nausea (24%), diarrhea (22%), vomiting (13%), constipation (11%), and decreased appetite. These are similar to semaglutide and tirzepatide but may be slightly more frequent at higher doses due to retatrutide's triple-agonist mechanism.

Q: Are retatrutide side effects worse than semaglutide?

Retatrutide side effects are similar in type to semaglutide (mainly GI issues like nausea and diarrhea). At the highest doses, retatrutide may cause slightly more GI side effects due to its additional glucagon receptor activity, but the overall tolerability profile is comparable. Most patients in trials completed treatment.

Q: Does retatrutide cause heart problems?

Clinical trials have not shown increased cardiovascular risk with retatrutide. In fact, Phase 2 data showed improvements in blood pressure, cholesterol, and triglycerides. A dedicated cardiovascular outcomes trial is expected as part of the approval process.

Q: How long do retatrutide side effects last?

Like other GLP-1 medications, retatrutide side effects are typically worst during the first 4-8 weeks of treatment and during dose increases. Most patients report significant improvement by weeks 8-12 as the body adjusts.

Q: Does retatrutide cause hair loss?

Hair loss was not reported as a significant side effect in retatrutide clinical trials. However, any medication that causes rapid weight loss can temporarily trigger telogen effluvium (stress-related hair shedding), which is typically reversible.

Q: Can retatrutide cause pancreatitis?

Pancreatitis is a known rare risk with GLP-1 class medications. In retatrutide trials, cases were extremely rare and consistent with rates seen with semaglutide and tirzepatide. Patients with a history of pancreatitis should discuss this risk with their doctor.

Short answer: Retatrutide side effects are similar to semaglutide and tirzepatide — mostly nausea, diarrhea, and vomiting that improve over time. As a triple agonist (GIP + GLP-1 + glucagon), it may cause slightly more GI effects at higher doses, but most trial participants completed treatment.

Updated April 2026 · Based on published Phase 2 (NEJM 2023) and Phase 3 TRIUMPH data · Educational content only

Quick Facts

Most common

Nausea (24%)
Diarrhea (22%)

Severity

Mostly mild to moderate
Improve over 8-12 weeks

Completion rate

~82% completed trials
Low discontinuation

Important: Retatrutide is not yet FDA-approved. All side effect data comes from clinical trials. Real-world side effects may differ once the drug becomes commercially available.

Common Retatrutide Side Effects (From Phase 2 Trial Data)

Like semaglutide and tirzepatide, retatrutide's most common side effects are gastrointestinal. These occur because all GLP-1 receptor agonists slow stomach emptying and affect gut signaling. Retatrutide's additional glucagon receptor activity may also contribute to mild GI effects.

Side Effect	Frequency (12mg dose)	vs Semaglutide	Severity
Nausea	~24%	Similar (44% semaglutide)	Mild to moderate
Diarrhea	~22%	Similar (30% semaglutide)	Mild to moderate
Vomiting	~13%	Lower (24% semaglutide)	Mild to moderate
Constipation	~11%	Lower (24% semaglutide)	Mild
Decreased appetite	Common	Similar	Desired effect
Heartburn/GERD	~8%	Similar	Mild
Increased heart rate	~2-4 bpm increase	Slightly higher	Mild, clinically insignificant

← Swipe to see all columns →

Key takeaway: Despite being a more powerful triple agonist, retatrutide's overall side effect rates are actually comparable to — and in some cases lower than — semaglutide. This may be because the glucagon component helps offset some GI effects.

Why Being a Triple Agonist Matters for Side Effects

Retatrutide is the world's first triple agonist, activating three receptors simultaneously:

GLP-1 Receptor

Reduces appetite, slows stomach emptying. Same mechanism as semaglutide. Main source of GI side effects.

GIP Receptor

Enhances insulin response and fat metabolism. Same addition as tirzepatide. May actually reduce nausea.

Glucagon Receptor

Unique to retatrutide. Increases energy expenditure and fat burning. May cause mild heart rate increase.

The glucagon receptor activation is what makes retatrutide unique. It boosts calorie burning and fat metabolism — contributing to the record-breaking 24-28% weight loss in trials. The trade-off is a small (2-4 bpm) heart rate increase that has been clinically insignificant so far.

Side Effects by Dose: Higher Dose = More Effects?

In the Phase 2 trial, retatrutide was tested at 1mg, 4mg, 8mg, and 12mg weekly doses. Side effects were dose-dependent — higher doses caused more GI effects but also more weight loss.

Dose	Avg Weight Loss	GI Side Effects	Discontinuation Rate
1 mg/week	~8.7%	Mild, infrequent	Very low
4 mg/week	~17.5%	Moderate	Low
8 mg/week	~22.8%	Moderate to noticeable	Low
12 mg/week	~24.2%	Most noticeable (still manageable)	~6%

Even at the highest 12mg dose — which produced the most dramatic weight loss — only about 6% of participants discontinued due to side effects. This is comparable to discontinuation rates seen with semaglutide and tirzepatide.

Serious Side Effects (Rare but Important)

Serious adverse events in retatrutide trials were rare and consistent with the known GLP-1 drug class risks:

Potential Serious Risks (Rare):

Pancreatitis — Inflammation of the pancreas. Extremely rare in trials. Risk is consistent with other GLP-1 drugs.
Gallbladder problems — Gallstones can form during rapid weight loss. Not unique to retatrutide.
Thyroid tumors — Seen in rodent studies with GLP-1 drugs. No human cases confirmed. Standard boxed warning for the drug class.
Severe GI events — Rare cases of severe nausea/vomiting requiring medical attention, typically during dose escalation.

These risks are not unique to retatrutide — they apply to the entire GLP-1 medication class including semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound).

Retatrutide vs Semaglutide vs Tirzepatide: Side Effect Comparison

Side Effect	Retatrutide	Semaglutide	Tirzepatide
Nausea	~24%	~44%	~25-30%
Diarrhea	~22%	~30%	~17%
Vomiting	~13%	~24%	~9-12%
Constipation	~11%	~24%	~6-7%
Heart rate increase	2-4 bpm	1-3 bpm	1-3 bpm
Avg weight loss	24-28%	~15%	~20-22%

Bottom line: Retatrutide produces significantly more weight loss than both semaglutide and tirzepatide, while its GI side effects are actually comparable or lower. The triple-agonist approach appears to improve the efficacy-to-side-effect ratio.

What to Expect: Side Effect Timeline

Based on clinical trial patterns and the known behavior of GLP-1 medications, here's the likely side effect timeline once retatrutide becomes available:

Weeks 1-4: Initiation Phase

Mild nausea and appetite changes. Low starting doses minimize initial effects. Most patients tolerate this well.

Weeks 4-12: Dose Escalation

Side effects peak during dose increases. Nausea and diarrhea most common. This is when most people who will experience GI effects feel them the strongest.

Weeks 12-24: Adaptation

Significant improvement in GI symptoms. Body adapts to the medication. Weight loss accelerates while side effects decline.

Month 6+: Maintenance

Most side effects resolved. Appetite suppression continues. Steady, ongoing weight loss with minimal discomfort.

Don't Want to Wait for Retatrutide?

Retatrutide won't be available until late 2026 at the earliest. Semaglutide and tirzepatide are available now through online providers — and many people lose 15-22% of their body weight.

Best Semaglutide Providers → Best Tirzepatide Providers →

Frequently Asked Questions

What are the most common retatrutide side effects?

The most common are nausea (~24%), diarrhea (~22%), vomiting (~13%), and constipation (~11%). These are gastrointestinal effects similar to other GLP-1 medications and typically improve within 8-12 weeks.

Is retatrutide safe?

Based on Phase 2 and early Phase 3 data, retatrutide has a safety profile similar to other GLP-1 medications. Most side effects are mild to moderate. However, it's still investigational and long-term data is limited.

Are retatrutide side effects worse than semaglutide?

No — in fact, Phase 2 data shows retatrutide may have lower rates of nausea, vomiting, and constipation than semaglutide, despite producing significantly more weight loss. The triple-agonist mechanism appears to improve tolerability.

Does retatrutide cause heart problems?

No cardiovascular problems have been found. Retatrutide may increase heart rate by 2-4 bpm (clinically insignificant). Phase 2 data showed improvements in blood pressure, cholesterol, and triglycerides.

How long do retatrutide side effects last?

Based on GLP-1 class patterns, side effects are worst during weeks 4-12 (dose escalation period) and improve significantly by week 12-16 as the body adjusts.

Does retatrutide cause hair loss?

Hair loss was not a significant side effect in trials. However, rapid weight loss from any cause can trigger temporary hair shedding (telogen effluvium), which is typically reversible.

What makes retatrutide different from other GLP-1 drugs?

Retatrutide is the first triple agonist (GIP + GLP-1 + glucagon). Semaglutide targets only GLP-1, and tirzepatide targets GIP + GLP-1. The added glucagon activity increases fat burning and energy expenditure, contributing to greater weight loss.

Can retatrutide cause pancreatitis?

Pancreatitis is a known rare risk with all GLP-1 medications. In retatrutide trials, cases were extremely rare. Patients with a history of pancreatitis should discuss this with their doctor.

Sources

1. Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM, 389(6), 514-526. 2. Eli Lilly and Company. (2024). TRIUMPH Phase 3 Program Updates. Press releases and investor presentations. 3. Rosenstock, J., et al. (2023). Retatrutide Phase 2 Trial in Type 2 Diabetes. NEJM, 389(6), 498-509. 4. Coskun, T., et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for obesity. Cell Metabolism.